The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2019

Filed:

May. 11, 2016
Applicants:

Biomérieux, Marcy l'etoile, FR;

Hospices Civils DE Lyon, Lyons, FR;

Centre Hospitalier Universitaire DE Nantes, Nantes, FR;

Inventors:

Bernard Allaouchiche, Lyons, FR;

Karim Asehnoune, Nantes, FR;

Marilyne Dupin, Vaugneray, FR;

Tanguy Fortin, Lyons, FR;

Aurélie Gouel-Cheron, Paris, FR;

Audrey Larue-Triolet, Tassin la Demi Lune, FR;

Guillaume Monneret, Lyons, FR;

Alexandre Pachot, Sulignat, FR;

Sylvie Pons, Saint Genis les Ollieres, FR;

Antoine Roquilly, Caulfield North, AU;

Fabienne Venet, Lyons, FR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); G01N 33/53 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/26 (2013.01); G01N 2800/50 (2013.01);
Abstract

A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a Δ value; and comparing the Δ value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.


Find Patent Forward Citations

Loading…